The Trump administration is contemplating allowing U.S. pharmaceutical companies to continue licensing deals with Chinese drugmakers despite broader restrictions on Chinese investments. According to Reuters, the Treasury Department is drafting rules that would permit American firms to invest in promising Chinese medicines not linked to bioweapon development. This approach contrasts with stricter measures advocated by some lawmakers and smaller U.S. biotech firms who fear such deals could make the U.S. overly reliant on China for new pharmaceuticals. Last year, licensing deals involving Chinese biotech companies were valued at $115 billion, with nearly half of all U.S. overseas drug licenses originating from China in 2025. Major pharmaceutical companies like Pfizer and Bristol Myers Squibb have been lobbying against sweeping restrictions, arguing that these collaborations do not pose national security risks.
Written locally by qwen2.5:14b on 2026-09-18,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
The Trump administration is considering allowing U.S. pharmaceutical companies to continue striking most licensing deals with Chinese drugmakers despite its broader crackdown on investment in China, according to people briefed on the plans.
uncertain
companies → consider → plans
Rules being drafted by the Treasury Department would likely allow American drugmakers to invest in promising medicines being developed by Chinese companies, provided they are not linked to pathogens or biotechnology that could potentially be weaponized, three sources told Reuters.
uncertain
sources → draft → Reuters
The approach would be considerably looser than restrictions sought by some lawmakers and smaller U.S. biotech companies, which argue that American investment is helping China challenge the U.S. for dominance of the pharmaceutical industry.
asserted
China → seek → industry
The proposed rules have not been finalized and could still change, particularly if President Donald Trump intervenes, the sources said.
uncertain
sources → propose → ?
Licensing deals involving Chinese biotech companies were worth $115 billion last year, according to research firm GlobalData, providing U.S. pharmaceutical companies with new drugs for their pipelines while funneling billions of dollars into Chinese firms.
uncertain
deals → involve → firms
Almost half of U.S. deals to license drugs from overseas in 2025 involved Chinese companies, GlobalData found, with the trend continuing this year.
asserted
trend → license → companies
Pfizer recently announced a collaboration worth up to $10.5 billion with China's Innovent Biologics covering 12 cancer programs, while Bristol Myers Squibb struck a partnership worth as much as $15.2 billion with Jiangsu Hengrui Pharma.
asserted
Squibb → announce → Pharma
Major pharmaceutical companies have been lobbying the Trump administration against sweeping restrictions.
asserted
companies → lobby → restrictions
Pfizer CEO Albert Bourla said he had discussed China and national security with Treasury Secretary Scott Bessent, Secretary of State Marco Rubio and officials at the Department of Health and Human Services.
asserted
he → say → Health
Bourla argued that licensing medicines developed by Chinese companies does not pose a national security threat.
asserted
licensing → argue → threat
"I don't think that that's the way to compete with China, to try to slow them down," he said.
asserted
he → think → them
"The important thing is to have a new medicine, and I don't see any national security concerns for something like that.
asserted
I → have → that
But some lawmakers and smaller biotech companies are pushing in the opposite direction, warning that continued investment could leave the U.S. strategically dependent on China for new medicines.
"
uncertain
investment → push → medicines
Are we okay with a strategic dependence on China for innovative drugs?" said Ginkgo Bioworks CEO Jason Kelly, who has urged Treasury officials to impose restrictions.
asserted
who → say → restrictions
"Because that's what we are currently doing with this offshoring."
asserted
we → do → offshoring
Republican Rep. John Moolenaar and Democratic Rep. Debbie Dingell are among lawmakers seeking tougher restrictions.
asserted
Moolenaar → seek → restrictions
Moolenaar has urged Treasury to use the COINS Act, a 2025 national security law restricting some outbound U.S. investment, to clamp down on pharmaceutical transactions involving China.
asserted
Moolenaar → urge → China
The pair are also sponsoring legislation that would tighten scrutiny of biotech investments, licensing agreements and joint ventures involving Chinese companies.
asserted
that → sponsor → companies
Moolenaar has argued that American money flowing into Chinese biotech is helping Beijing move rapidly up the pharmaceutical industry's value chain.
asserted
Beijing → argue → chain
Other lawmakers disagree.
asserted
lawmakers → disagree → ?
Democratic Rep. Jake Auchincloss, whose Massachusetts district includes numerous life-sciences companies, said attempts to contain China's pharmaceutical industry by restricting American investment were unlikely to succeed.
asserted
attempts → include → investment
"China is spending 100 billion dollars on biotechnology.
asserted
China → spend → biotechnology
China has brilliant scientists," he said.
asserted
he → have → scientists
Treasury and the White House declined to comment on the proposed rules.
asserted
Treasury → decline → rules
The deliberations come ahead of Chinese President Xi Jinping's expected meeting with Trump in the U.S. next week.
asserted
deliberations → come → U.S.
The new pharmaceutical investment rules are not expected to be unveiled before that meeting, according to people briefed on the process.
uncertain
rules → expect → process
The Aporia
